These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 15564310

  • 1. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M.
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [Abstract] [Full Text] [Related]

  • 2. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease.
    Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS.
    Clin Immunol; 2005 Oct; 117(1):48-56. PubMed ID: 15961346
    [Abstract] [Full Text] [Related]

  • 3. Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with active systemic lupus erythematosus.
    Komatsuda A, Wakui H, Iwamoto K, Togashi M, Maki N, Masai R, Hatakeyama T, Sawada K.
    Clin Immunol; 2007 Oct; 125(1):26-9. PubMed ID: 17683987
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M.
    Anticancer Res; 2001 Oct; 21(4B):3053-9. PubMed ID: 11712810
    [Abstract] [Full Text] [Related]

  • 6. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA, El-Gendi HI, Ahmed HH.
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [Abstract] [Full Text] [Related]

  • 7. Up regulation of serum tumor necrosis factor-related apoptosis inducing ligand in juvenile-onset systemic lupus erythematosus: relations with disease activity, antibodies to double -stranded DNA, nephritis and neutropenia.
    Ezzat MH, El-Gammasy TM, Shaheen KY, El-Mezdawi RA, Youssef MS.
    Int J Rheum Dis; 2013 Jun; 16(3):310-8. PubMed ID: 23981753
    [Abstract] [Full Text] [Related]

  • 8. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA.
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
    Habib HM, Taher TE, Isenberg DA, Mageed RA.
    Scand J Rheumatol; 2009 Feb; 38(2):112-20. PubMed ID: 19110660
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
    Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F.
    Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
    [Abstract] [Full Text] [Related]

  • 13. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ.
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [Abstract] [Full Text] [Related]

  • 14. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.
    Bijl M, Bootsma H, Van Der Geld Y, Limburg PC, Kallenberg CG, Van Rijswijk MH.
    Ann Rheum Dis; 2004 Jul; 63(7):831-5. PubMed ID: 15194579
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
    Sabry AA, Elbasyouni SR, Kalil AM, Abdel-Rahim M, Mohsen T, Sleem A.
    Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus.
    Her M, Kim D, Oh M, Jeong H, Choi I.
    Lupus; 2009 May; 18(6):501-7. PubMed ID: 19395451
    [Abstract] [Full Text] [Related]

  • 20. Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in Wegener's granulomatosis, systemic lupus erythematosus and chronic renal failure.
    Mrowka C, Sieberth HG.
    Clin Nephrol; 1995 May; 43(5):288-96. PubMed ID: 7543387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.